1. Introduction {#sec1-viruses-10-00729}
===============

Cancer of the cervix uteri, more commonly known as cervical cancer, is an important public health concern. It was reported as the fourth most frequently occurring gynecological cancer, with an estimated worldwide incidence of 528,000 cases and 266,000 deaths in 2012 \[[@B1-viruses-10-00729]\]. In Europe, an estimated 58,373 women are diagnosed annually with cervical cancer, and 24,404 of those die from this illness \[[@B2-viruses-10-00729]\].

The incidence and mortality of cervical cancer, however, have been declining in developed countries due to the discovery of the Pap test in the 1940s, which enabled the prompt identification of morphological changes in the cervical epithelium \[[@B3-viruses-10-00729]\]. The use of the Pap test in national screening programs can be dated back to the 1960s and 1970s \[[@B4-viruses-10-00729]\], and it is still a cornerstone in the majority of current programs. Moreover, the International Agency for Research on Cancer (IARC) determined that the incidence of invasive cervical cancer can be reduced by at least 80% with the implementation of cervical cancer screening programs based on Pap test every three to five years for women of ages 35 to 64 \[[@B5-viruses-10-00729],[@B6-viruses-10-00729],[@B7-viruses-10-00729],[@B8-viruses-10-00729],[@B9-viruses-10-00729]\].

Cervical cancer screening was revolutionized in the early 1980s by the discovery of human papillomaviruses (HPV) as the single causative agents of the disease. In 1983, HPV type 16 (HPV16) was first identified in DNA from a biopsy sample of invasive cancer of the cervix, and in the following years, HPVs were reported as the main causative agents of cervical cancer \[[@B10-viruses-10-00729],[@B11-viruses-10-00729],[@B12-viruses-10-00729],[@B13-viruses-10-00729]\]. HPVs are small non-enveloped double-stranded DNA viruses with 221 officially characterized types, as of June 2018 \[[@B14-viruses-10-00729]\]. These viruses have a genome of 8 kb that encodes early regulatory proteins (E1, E2, E5, E6, and E7), and late structural proteins (L1 and L2). HPVs are the most common sexually transmitted viruses \[[@B15-viruses-10-00729],[@B16-viruses-10-00729],[@B17-viruses-10-00729]\]. According to estimates, approximately 80% of sexually active women will acquire the infection in their lifetime, and in the majority of cases (\>90%), it will be a transient, asymptomatic infection cleared by the immune system in six months to two years \[[@B17-viruses-10-00729],[@B18-viruses-10-00729],[@B19-viruses-10-00729]\]. Only after a persistent infection can HPV lead to low- and/or high-grade cervical intraepithelial neoplasia (CIN), which may eventually evolve to cervical cancer \[[@B17-viruses-10-00729],[@B20-viruses-10-00729],[@B21-viruses-10-00729]\]. However, not all HPV types have been linked to cervical cancer. At least 12 types of HPV are epidemiologically classified as oncogenic, high-risk (hr) types (HPV16/18/31/35/39/45/51/52/56/58/66/68), which cause more than 97% of cervical cancer cases, while low-risk (lr) types (HPV6/11/40/42/43/44/54/61/72) are linked to anogenital warts and laryngeal papillomas \[[@B16-viruses-10-00729],[@B22-viruses-10-00729],[@B23-viruses-10-00729],[@B24-viruses-10-00729]\]. The aforementioned HPV16 and HPV18 are the most commonly occurring hrHPV types, and cause approximately 70% of cervical cancers (\~50% HPV16, \~20% HPV18) \[[@B17-viruses-10-00729],[@B25-viruses-10-00729],[@B26-viruses-10-00729]\]. The elucidation of the etiological role of HPV has altered the landscape of cervical cancer screening in more ways than one. The fact that cervical cancer is primarily attributable to a single infectious agent enabled the development of new more sensitive HPV-based screening tests for secondary prevention of cervical cancer and three vaccines against HPV, which are utilized for primary prevention.

This review focuses on the available tests and strategies, which are currently employed for screening and prevention of HPV infection and cervical cancer. Furthermore, in accordance with recommendations specified in the recent European Guidelines, important aspects of screening programs necessary for the success and efficiency of such systems are highlighted. Finally, the current landscape of cervical cancer screening programs of member states of the European Union (E.U.) and some associated countries is reviewed.

2. Methodologies for Cervical Cancer Screening {#sec2-viruses-10-00729}
==============================================

2.1. Cervical Cytology {#sec2dot1-viruses-10-00729}
----------------------

### 2.1.1. Conventional Pap Test and Its Alternatives {#sec2dot1dot1-viruses-10-00729}

Testing to identify anomalies in the cervix can be dated as far back as the early 19th century, when anatomists and pathologists of the time observed and studied the cytological changes derived from cervical and other genital neoplasms, as well as the woman's menstrual cycle \[[@B27-viruses-10-00729]\]. In the mid-1800s, the Irish physician Walter Hayle Walsh was the first to show that cancerous cells could be identified by microscopy \[[@B28-viruses-10-00729],[@B29-viruses-10-00729]\]. In the early 20th century (1927), the Romanian physician Aurel Babeş detected the presence of cervical cancer by collecting cells from a woman's cervix using a platinum loop and then observing them under a microscope. This process was the predecessor to what is known today as the Pap test \[[@B29-viruses-10-00729]\].

With the invention of the Pap test in the 1940s, by George N. Papanicolaou and H.F. Traut, cervical cytology gained a robust and low-complexity method of screening for cervical cancer \[[@B30-viruses-10-00729]\]. This process entails the exfoliation of cells from the cervix, which are then fixed, viewed under a microscope, and are subsequently morphologically interpreted. The staining method developed for this test offered a polychromatic definition of the nucleus and the features of the cytoplasm. The Pap test allows the assessment of nuclear chromatin alterations to discern whether necrosis occurred, the observation of the degree of cellular degeneration, and the distinction of the maturity of squamous epithelial cells \[[@B28-viruses-10-00729],[@B30-viruses-10-00729],[@B31-viruses-10-00729]\].

Despite its widespread use as the primary cervical cancer screening method, the Pap test has some important limitations. The staining procedure of the conventional Pap test requires a considerable amount of time (20--30 min) and consumables \[[@B32-viruses-10-00729]\]. The smearing process of the Pap test is also characterized by poor reproducibility and is vulnerable to obscuration by blood and mucus, imperfect fixation, and a non-uniform distribution of cells, thus causing errors in the detection and interpretation of the results. These issues can be attributed partly to the quality of sampling and can explain the broad range of sensitivity (30--87%) reported for the Pap test \[[@B33-viruses-10-00729],[@B34-viruses-10-00729]\].

Consequently, to address the shortcomings of the Pap test, a number of derivative methods were developed, such as the UltraFast staining technique, the short-duration Papanicolaou stain, the REAP stain and the Enviro-Pap method \[[@B32-viruses-10-00729],[@B35-viruses-10-00729],[@B36-viruses-10-00729],[@B37-viruses-10-00729],[@B38-viruses-10-00729],[@B39-viruses-10-00729]\]. These modifications significantly improved upon the conventional Pap smear performance in terms of speed and cost, and are also more environmentally friendly. The guiding principle of these enhancements was to improve at least one aspect of the smear without compromising the quality of the results \[[@B32-viruses-10-00729],[@B35-viruses-10-00729],[@B36-viruses-10-00729],[@B37-viruses-10-00729],[@B38-viruses-10-00729]\].

### 2.1.2. Liquid-Based Cytology {#sec2dot1dot2-viruses-10-00729}

Another alternative method developed to address the shortcomings of the conventional Pap smear is liquid-based cytology (LBC). ThinPrep® Pap test (Hologic, Inc, Marlborough, MA) was the first LBC technique to be approved by the United States Food and Drug Administration (FDA) \[[@B34-viruses-10-00729]\]. This method entails the collection of cells from the cervix, which are then transferred to a vial containing preservative solution instead of being fixed on a slide, thus enabling uniform distribution of the collected clinical material. Since only a portion of the sample is used for cytology, the rest can be employed for further testing, including HPV testing \[[@B33-viruses-10-00729],[@B40-viruses-10-00729]\]. Presently, Thin Prep and SurePath (Becton Dickinson) are the two most frequently used LBC techniques. Several studies have shown significantly reduced numbers of unsatisfactory smears that would require repeat testing when LBC is used and some studies have also shown higher CIN detection rates compared to the conventional Pap test \[[@B34-viruses-10-00729],[@B41-viruses-10-00729],[@B42-viruses-10-00729]\]. Conversely, other studies have questioned the advantages of LBC over the conventional Pap test and showed sensitivity less than or equal to that of the conventional Pap test \[[@B41-viruses-10-00729],[@B43-viruses-10-00729],[@B44-viruses-10-00729],[@B45-viruses-10-00729],[@B46-viruses-10-00729]\].

### 2.1.3. Visual Inspection by Acetic Acid and Visual Inspection with Lugol's Iodine {#sec2dot1dot3-viruses-10-00729}

Visual inspection by acetic acid (VIA) or with Lugol's iodine (VILI) are two inexpensive screening methods frequently used in low-resource settings, with VIA being more widely used. These techniques are based on the fact that upon the application of acetic acid or Lugol's iodine directly to the cervix, precancerous cervical lesions become discernible to the naked eye by both clinicians and nonclinicians. Although not perfect, both VIA and VILI have been reported to have acceptable specificity and sensitivity in low-resource settings \[[@B47-viruses-10-00729],[@B48-viruses-10-00729],[@B49-viruses-10-00729]\].

Cervical cytology has undoubtedly played an important role in cervical cancer screening and continues to do so. However, it has inherited the limitation of being a morphological method requiring subjective interpretation by well-trained cytologists \[[@B11-viruses-10-00729]\]. Despite continuous efforts to improve the performance of cervical cytology, its sensitivity is not optimal and the method still produces high numbers of borderline results, such as atypical squamous cells of undetermined significance (ASCUS, or ASC-US after the 2001 Bethesda Workshop) which, require further testing, tight follow-up and raise constant uncertainty for false negative results leading to over-referral to colposcopy and overtreatment \[[@B11-viruses-10-00729],[@B50-viruses-10-00729],[@B51-viruses-10-00729],[@B52-viruses-10-00729]\].

2.2. HPV Testing {#sec2dot2-viruses-10-00729}
----------------

### 2.2.1. Advantages and Limitations {#sec2dot2dot1-viruses-10-00729}

In contrast to screening methods based on cytology, HPV testing does not rely on morphological interpretation and is based on the detection of HPV DNA, HPV mRNA or other viral markers. In the last two decades, HPV testing has become in several countries an invaluable part of clinical guidelines for cervical carcinoma screening, triage and follow-up after treatment \[[@B53-viruses-10-00729]\]. As a general rule, HPV testing must be performed in appropriate, evidence-based contexts to maximize the benefit and reduce over-diagnosis. HPV testing for the identification of women at higher risk of developing cervical cancer, significantly differs from molecular testing for other medically relevant viruses, in that analytic sensitivity for the detection of HPV is not the prime driver of test performance. Unfortunately, the great majority of HPV tests currently on the market have high analytic sensitivity. Consequently, when they are used for agreed clinical indications they can yield a large number of clinically insignificant positives, resulting in more false referrals for colposcopy and biopsy, decreased correlation with the histological presence of disease, unnecessary treatment of healthy women and a consequent distrust of a positive result by the treating physician. Another important peculiarity of HPV testing for identification of women at higher risk for the development of cervical cancer is the need for balanced and artificially reduced coverage of the HPV testing types.

### 2.2.2. Clinical Validation of HPV Tests {#sec2dot2dot2-viruses-10-00729}

Taking into consideration these characteristics of HPV testing, when designing an HPV test to be used for agreed clinical indications, the ultimate sensitivity for the detection of precancerous lesions by inclusion of HPV types that are rarely associated with cervical cancer, must be carefully weighed against the potentially dramatic loss of clinical specificity when a particular HPV type (e.g., HPV53 and HPV66) is frequent in low-grade disease or in women without disease. In addition, it should always be taken into consideration that absolute reassurance following a negative cervical cancer screening test result is not achievable at any analytic sensitivity, because of a myriad of factors that are independent of the actual screening test performance, including operator error and poor cervical sampling. Thus, a cervical cancer screening program should adopt an HPV test for use as screening tool, only if it has been validated by demonstrating reproducible and consistently high sensitivity for CIN2+ and CIN3+ lesions, as well as minimal detection of clinically irrelevant, transient HPV infections \[[@B54-viruses-10-00729],[@B55-viruses-10-00729]\]. There is a consensus in the HPV community that HPV tests (neither commercial nor in-house tests) that have not been clinically validated should not be used in clinical practice. HPV testing should be performed only on samples processed and analyzed in qualified laboratories, validated by authorized accreditation bodies and in compliance with international standards \[[@B54-viruses-10-00729],[@B55-viruses-10-00729]\]. Laboratories involved in HPV-based screening should perform a minimum of 10,000 HPV tests per year \[[@B54-viruses-10-00729],[@B55-viruses-10-00729]\].

Several comprehensive inventories of commercially available HPV tests were published in the last decade \[[@B56-viruses-10-00729],[@B57-viruses-10-00729],[@B58-viruses-10-00729]\]. As of July 2018, at least 250 distinct commercial tests for detection of alpha HPVs and at least 230 variants of the original tests are available at the global market. Unfortunately, only a subset of commercial HPV tests has documented clinical performance for agreed indications for HPV testing in current clinical practice. For more than half of the HPV tests in the global market, no single publication in peer-reviewed literature can be identified \[[@B58-viruses-10-00729]\]. In contrast to commercial kits for "classical" molecular microbiology targets, the great majority of HPV commercial tests currently on the market do not contain a sample extraction step and a number of them do not even mention recommended nucleic acid extraction methodology in their manufacturer's instructions. Only a minority of HPV tests on the market have internal controls \[[@B58-viruses-10-00729]\].

As a multitude of hrHPV tests are available, regular evaluation updates are essential to ensure their suitability for primary cervical cancer screening. A recent systematic review \[[@B59-viruses-10-00729]\], listed the hrHPV DNA tests that were either validated through randomized trials showing a very low incidence of cervical cancer after a negative hrHPV DNA test \[[@B53-viruses-10-00729],[@B60-viruses-10-00729]\] or fulfilling consensus-based international equivalence criteria based on cross-sectional data \[[@B8-viruses-10-00729]\]. The international equivalence criteria are based on the non-inferior cross-sectional accuracy of a new HPV test versus one of the two benchmark comparator tests (GP5+/6+ PCR-EIA and/or Qiagen Hybrid Capture 2 HPV DNA Test) that have been validated in clinical trials and detect the same molecular targets, i.e., DNA of hrHPV types \[[@B61-viruses-10-00729]\]. To fulfill the necessary criteria, the candidate test should demonstrate a relative sensitivity and specificity to detect CIN2+ compared to the standard comparator tests of more than 0.90 and 0.98 respectively, and show high inter- and intra-laboratory reproducibility \[[@B61-viruses-10-00729]\]. Other potential cervical cancer screening tests based on other target molecules such as HPV mRNA, proteins or methylation markers cannot directly be considered equivalent and require additional evidence regarding their longitudinal effects, i.e., long-term safety \[[@B59-viruses-10-00729]\]. The proper validation of HPV DNA tests, according to the international equivalence criteria can be problematic due to difficulties with obtaining an appropriate set of clinical specimens. The recently launched international framework "Validation of HPV Genotyping Tests (VALGENT)" facilitates the comparison and validation of HPV DNA tests by providing a set of samples obtained from women attending routine screening (1,000--1,300 samples) enriched with cytological abnormal samples (300 samples) \[[@B62-viruses-10-00729]\]. In order to allow comparison with other HPV tests, each VALGENT panel includes a comparator assay that was previously clinically validated for cervical cancer screening purposes \[[@B62-viruses-10-00729]\]. As of July 2018, only 14 commercial HPV assays (out of +480 HPV assays at the global market) can be considered as completely or partially validated for primary HPV-based cervical cancer screening \[[@B59-viruses-10-00729],[@B62-viruses-10-00729]\]. The list includes four out of five HPV assays approved by US FDA: Hybrid Capture 2 (hc2) HPV DNA Test (Qiagen), cobas 4800 HPV Test (Roche), APTIMA HPV Assay (Hologic) and BD Onclarity HPV Assay (Becton Dickinson).

Since the performance of an HPV test may vary depending on the sample collection procedures and medium, regulatory approval in some settings requires validation of performance based on the choice of sample collection medium. Importantly, the validation of a pre-approved assay for use with a specific medium is a simpler process than de novo clinical validation of an HPV assay. It can be expected that several previously approved tests will eventually be validated for use with the most commonly used collection media \[[@B58-viruses-10-00729]\].

It is worth mentioning that although we have an increasing understanding of which HPV tests are valid for HPV-based primary cervical cancer screening, given an internationally accepted and applied validation framework and published professional guidance, we do not have widely accepted equivalent metrics to judge the validity of HPV tests in other clinical settings, including post-treatment surveillance and the triage of low-grade abnormalities \[[@B58-viruses-10-00729],[@B59-viruses-10-00729]\]. International efforts to create such validation guidelines will be of great benefit, since existing data show significant variation in commercially available tests being used in clinical settings that are not part of HPV-based primary cervical cancer screening programs.

3. Primary Cervical Cancer Prevention by HPV Vaccination {#sec3-viruses-10-00729}
========================================================

3.1. HPV Vaccines {#sec3dot1-viruses-10-00729}
-----------------

The identification of HPV as the main etiological agent of cervical cancer, presented novel opportunities for the development of preventative modalities against cervical cancer \[[@B10-viruses-10-00729]\]. With this knowledge, it became clear that stopping hr types of the virus from ever infecting should be explored as an option, in addition to the preexisting cervical cancer screening tests. Two decades long efforts culminated in 2006 with the approval of the first safe and efficacious HPV prophylactic vaccine \[[@B63-viruses-10-00729]\]. The first vaccine that was approved was the quadrivalent Gardasil/Silgard, which targets HPV6, 11, 16, and 18 \[[@B64-viruses-10-00729]\]. A year later, the bivalent Cervarix vaccine targeting HPV16 and 18 was approved, and more recently, the nonavalent Gardasil 9 vaccine, which targets HPV6, 11, 16, 18, 31, 33, 45, 52, and 58 was also approved \[[@B65-viruses-10-00729]\]. All three of these vaccines target HPV16 and 18, and contain HPV L1 protein virus-like particles (VLPs) expressed in different cell types \[[@B16-viruses-10-00729]\]. VLPs are morphologically and antigenically similar to native HPV virions, and because of the genomic similarity between different types of the virus, a certain degree of protection against HPV types not targeted by the vaccine, so called cross-protection, is also achieved. HPV vaccines elicit immunity through the production of high titers of anti-HPV IgG neutralizing antibodies, which block the entrance of the virus into the host cells \[[@B15-viruses-10-00729]\]. The quadrivalent and nonavalent vaccines contain VLPs of two lrHPV types, 6 and 11, which are responsible for more than 90% of anogenital warts and laryngeal papillomas. Moreover, the nonavalent vaccine is targeted against the five types (HPV31, 33, 45, 52, 58) most frequently identified in cervical cancer after HPV16 and 18 \[[@B16-viruses-10-00729],[@B66-viruses-10-00729],[@B67-viruses-10-00729]\]. Nonetheless, even with cross-protection and the increased number of HPV types covered by the nonavalent vaccine, HPV vaccines do not protect against all HPV types that cause cervical cancer \[[@B68-viruses-10-00729],[@B69-viruses-10-00729]\].

3.2. Improving HPV Vaccination Coverage {#sec3dot2-viruses-10-00729}
---------------------------------------

Initially, all three HPV vaccines had been approved for a 3-dose series in order to generate sufficient and long-lasting protective immunity \[[@B70-viruses-10-00729]\]. Currently, for all three vaccines two doses are recommended for persons starting the series before their 15th birthday and three dose schedule for those who start the series on or after their 15th birthday and for persons with certain immunocompromising conditions \[[@B71-viruses-10-00729]\]. Decreasing the number of doses not only leads to reductions in overall cost, which is a concern (especially in low-income countries), but it also increases adherence to the program \[[@B71-viruses-10-00729],[@B72-viruses-10-00729],[@B73-viruses-10-00729]\].

Despite their potency in providing protection against HPV infection, HPV vaccines are not therapeutic, as they are not effective in curing preexisting HPV infections \[[@B16-viruses-10-00729]\]. Hence, current HPV vaccination programs are mainly targeted to both genders prior to coitarche, aiming to reduce the burden of cervical cancer and other HPV-related tumors, not only in vaccinated but also in unvaccinated individuals thanks to herd immunity \[[@B69-viruses-10-00729]\]. As both genders are responsible for HPV transmission, both genders should be vaccinated to share the burden in reducing the risk of HPV-related disease, as well as to have equal access to direct vaccine benefits. It is becoming evident that only gender-neutral vaccination will lead to substantial control of HPV-related diseases both in women and men as well as maximizing prevention of cervical cancer, especially if vaccination coverage for girls in a particular program is not high. Current failure to implement gender-neutral HPV vaccination with high coverage in the great majority of countries looks like a missed unique public health opportunity \[[@B74-viruses-10-00729],[@B75-viruses-10-00729]\]. However, even with the high protection against de novo HPV infections provided by HPV vaccines, successful cervical cancer prevention will still rely on screening for years to come \[[@B69-viruses-10-00729]\] but future strategies will require substantial changes: longer screening intervals, exclusive use of HPV-based screening strategies as well as vaccination of older cohorts. An innovative strategy with the purpose of accelerating the reduction of cervical cancer incidence and mortality named "HPV-FASTER" has been recently proposed, with a generalized HPV vaccination campaign aimed at girls and women aged 9--45, paired with at least one HPV-based screening test at any age over 30 and eventual triage and diagnostic assessments among women who screen HPV-positive \[[@B76-viruses-10-00729]\].

4. Cervical Cancer Screening Programs {#sec4-viruses-10-00729}
=====================================

4.1. Organization of Screening {#sec4dot1-viruses-10-00729}
------------------------------

With extensive knowledge of the biology of cervical cancer and with an arsenal of screening and prevention tools, the disease can be detected at an early enough stage to be curable. As a concept, the fundamental principles of cervical cancer screening can be dated back as far as the 1940s, before organized screening programs took place \[[@B4-viruses-10-00729],[@B77-viruses-10-00729]\]. However, it was not until 1968 that Wilson and Jungner defined a set of criteria (comprehensively reviewed by Basu et. al. \[[@B47-viruses-10-00729]\]) that not only helped to define whether a disease, such as cervical cancer, is eligible for screening but also influenced the development of better-thought-out screening programs. Undertakings of such magnitude, however, are no trivial tasks, since a number of prerequisites have to be accounted for before embarking on the implementation of such programs. The nature and parameters of the program, which are directly influenced and supported by scientific progress, must be established \[[@B47-viruses-10-00729],[@B78-viruses-10-00729]\].

To this end, the first edition of the European Guidelines for Quality Assurance in Cervical Cancer Screening, published in 1993 \[[@B79-viruses-10-00729]\], designated the principles for organized, population-based screening, with a number of countries adhering to this recommendation \[[@B80-viruses-10-00729]\]. The supplements of the second edition of the European Guidelines for Quality Assurance in Cervical Cancer Screening of 2015 (the original volume of the second edition was published in 2008) emphasize the importance of the implementation of an organized, population-based cervical cancer screening program with a call/recall invitation system in order to take full advantage of the benefits of screening and discuss the key aspects of this type of organization in considerably increased detail \[[@B55-viruses-10-00729],[@B80-viruses-10-00729]\]. Such a program should have a national/regional team that directs the implementation of guidelines, rules and procedures. This team would also be responsible for quality assurance to monitor and to guarantee that all levels of the process are performed sufficiently. This responsibility includes the management and coordination of the call/recall system, testing and diagnosis, as well as follow-up after positive test results. Furthermore, quality assurance procedures call for attention to training personnel, evaluating performance, auditing and monitoring, and reviewing the impact of the program on the burden of disease. The latter is facilitated by the population-based nature of the program, which is characterized by the identification and personal invitation of each member of the targeted population eligible for screening \[[@B6-viruses-10-00729],[@B81-viruses-10-00729],[@B82-viruses-10-00729]\].

In contrast to organized population-based screening, opportunistic screening depends on the initiative of the individual woman and/or her doctor. This type of screening often results in high coverage only in certain parts of the population, which are screened frequently, while other parts of the population, usually with a lower socioeconomic status, exhibit lower coverage. This situation results in uneven coverage with heterogeneous quality, limited effectiveness, and reduced cost-effectiveness, as well as difficulty in monitoring the population \[[@B81-viruses-10-00729]\].

Thus, as the European Guidelines recommend, a program with an organized population-based nature may substantially improve the accessibility and equity of screening access while simultaneously improving effectiveness and cost-effectiveness \[[@B6-viruses-10-00729],[@B81-viruses-10-00729]\]. The key factors to be specified within such a program are the target age, screening intervals, and screening algorithm. The latter refers to the primary screening test and the subsequent management of results at each step of the algorithm.

4.2. Primary Screening Tests and Specifications {#sec4dot2-viruses-10-00729}
-----------------------------------------------

### 4.2.1. Primary Cytology Testing {#sec4dot2dot1-viruses-10-00729}

Three options that are currently in use for primary cervical cancer screening, are cytology, HPV testing, and cotesting \[[@B83-viruses-10-00729]\]. Cytology-based testing has been used for primary screening for more than half a century and is currently employed by the majority of screening programs in Europe. However, it was implemented in screening programs in the 1960s-70s without being assessed in RCTs \[[@B47-viruses-10-00729]\]. As described earlier in this review, cytology-based testing has various technical characteristics that affect its standing at the forefront of screening. It has undoubtedly proven its impact on reducing cervical cancer morbidity and mortality, especially in organized settings \[[@B84-viruses-10-00729]\]. However, the low sensitivity of the technique, the requirement for high-quality diagnostic facilities, the high costs needed to sustain the infrastructure, and the need for highly trained personnel are important issues that have brought primary cytology screening under intense scrutiny for the past twenty years \[[@B85-viruses-10-00729],[@B86-viruses-10-00729]\]. To maintain the accuracy and performance of cervical cytology, short intervals between screenings are required, which implies the performance of an increased number of tests and as such it can be costly \[[@B83-viruses-10-00729]\]. Another factor that is already affecting the performance of cytology as a tool for primary screening is a reduced population burden of HPV due to HPV vaccination. The specificity of cytology, the main hallmark of the method, is decreasing in countries with high HPV coverage due to the dramatic population reduction of high-grade lesions as a result of HPV vaccination. Furthermore, since the current vaccines do not cover all HPV types causing cervical abnormalities, an increase in proportion of minor abnormalities caused by less carcinogenic HPV types is also expected, which in turn will further lower the once very high positive predictive value (PPV) of cytology \[[@B84-viruses-10-00729],[@B87-viruses-10-00729]\]. As the population prevalence of hrHPVs and consequently CIN2/3 will decrease, screening modalities with higher sensitivity like HPV testing will clearly perform better at the population level.

### 4.2.2. Primary HPV Testing {#sec4dot2dot2-viruses-10-00729}

The development of clinically validated HPV tests, which are more accurate and sensitive than primary cytology testing, has recently caused a paradigm shift. According to the European Guidelines, as well as the World Health Organization (WHO), HPV testing is now proposed as the primary screening tool for cervical cancer \[[@B55-viruses-10-00729],[@B88-viruses-10-00729]\]. HPV testing is characterized by high clinical sensitivity, a high negative predictive value (NPV), objectiveness, low training requirements, reproducibility and a high throughput capacity \[[@B47-viruses-10-00729],[@B88-viruses-10-00729],[@B89-viruses-10-00729]\]. HPV-based screening requires longer screening intervals than cytology-based screening since progression to cancer occurs years after an infection with hrHPV. Based on these facts, the European Guidelines recommend a five-year screening interval for HPV testing, which may be extended up to 10 years depending on the age and screening history of the patient \[[@B47-viruses-10-00729],[@B55-viruses-10-00729],[@B90-viruses-10-00729],[@B91-viruses-10-00729]\]. Longer screening intervals contribute to less expensive programs, as well as providing a longer duration of "peace of mind" when women test negative in comparison to cytology-negative women \[[@B47-viruses-10-00729],[@B91-viruses-10-00729]\]. Another factor that is expected to help establish primary HPV screening as a more cost-effective option is HPV vaccination. In a study performed to evaluate the effectiveness and cost-effectiveness of cervical cancer prevention scenarios, the most cost-effective strategy was the combination of preadolescent vaccination with an organized screening program, using primary HPV testing every five years with cytology triage \[[@B92-viruses-10-00729]\]. In this regard, partial HPV genotyping may be worth employing either as part of primary HPV screening, which would entail using an HPV assay with genotyping capabilities, or as triage. This approach would not only help with the management of positive HPV cases but would also enable the direct monitoring of the downstream effects of vaccination \[[@B83-viruses-10-00729],[@B84-viruses-10-00729],[@B91-viruses-10-00729],[@B93-viruses-10-00729]\].

When deciding at what age to start HPV-based screening it is important to take into account the natural history of HPV infection in order to avoid unnecessary follow-up and/or overtreatment of women with only transient HPV infections \[[@B47-viruses-10-00729],[@B94-viruses-10-00729]\]. Thus, the European Guidelines recommend against primary HPV screening before the age of 30 and are in favor of screening starting at the age of 35, especially in a setting without prior cytology screening implemented. However, there is insufficient evidence to promote or restrict the start of HPV-based screening between the ages of 30--34. Conversely, in a region or country where primary cytology screening is running well, the policy-makers of the program may decide to implement primary HPV testing beginning at the recommended age of 30 or 35, while also maintaining their current cytology-based program from the ages of 20-30, at least until evidence shows otherwise. Nonetheless, the avoidance of screening prior to the age of 20 is recommended \[[@B53-viruses-10-00729],[@B55-viruses-10-00729],[@B91-viruses-10-00729]\].

At the same time, setting the age to stop screening is important. The European Guidelines suggest that primary HPV screening could stop at the same age recommended for cytology, that is, at 60--65 years of age, provided that the most recent screening test was negative \[[@B55-viruses-10-00729]\]. The reasoning for stopping screening at this age is due to the extremely low probability that an incident HPV infection will become persistent and that women will consequently develop cancer. Screening for a newly acquired HPV infection is therefore redundant and/or not cost-effective in women over 65 years with recent negative screen result(s) \[[@B95-viruses-10-00729],[@B96-viruses-10-00729]\]. Furthermore, RCT data report significantly less CIN2/3 at ages 50--60 in comparison to 35--49 \[[@B60-viruses-10-00729],[@B97-viruses-10-00729]\]. However, the European Guidelines state that current data are insufficient to select the optimal age to stop HPV primary testing, which was why the recommended age to stop screening for cytology was also kept for primary HPV testing. Nonetheless, it is important to note that cytology performs relatively poor at those ages, especially for postmenopausal women, in whom epithelial atrophy is commonly observed. Moreover, the cervical transformation zones of postmenopausal women are situated in the cervical canal, making the collection of material for cytological examination less accessible. Accordingly, cytology has low sensitivity for postmenopausal women, and screening can result in elevated false-positive results \[[@B95-viruses-10-00729],[@B98-viruses-10-00729]\]. However, a recent Swedish study found that although HPV prevalence is relatively low in older women, there was still an increased risk for cervical dysplasia upon a second positive HPV screen test \[[@B98-viruses-10-00729]\]. Furthermore, 30% of cervical cancer cases were still diagnosed in women older than 60, with a mortality as high as 70%. These findings, coupled with the non-optimal performance of cytology in older women, suggest the extension of the screening age as well as the need for more research \[[@B98-viruses-10-00729]\].

### 4.2.3. Primary HPV Cotesting {#sec4dot2dot3-viruses-10-00729}

Cotesting combines the sensitivity of HPV testing with the specificity of cytology at the level of primary screening. Even though some non-European studies reported marginal superiority of cotesting over HPV-based screening alone, the European Guidelines recommend against cotesting at any given age because it is not substantially more effective than HPV testing and is considerably more costly \[[@B55-viruses-10-00729],[@B83-viruses-10-00729],[@B89-viruses-10-00729]\].

4.3. Management of Women after Primary Screening {#sec4dot3-viruses-10-00729}
------------------------------------------------

### 4.3.1. Management of Women after a Positive HPV Primary Test Result {#sec4dot3dot1-viruses-10-00729}

Having established HPV testing as the recommended primary screening method, the age range, and the screening intervals of a negative test, it is important to specify the management of positive results from primary testing. Triaging women with a positive HPV primary test result can compensate for the lower specificity that characterizes HPV testing. In this regard, the European Guidelines recommend the performance of cytology as the main triage test in order to manage the increased number of screen positives identified by primary HPV testing, which would otherwise lead to an excessive number of referrals to colposcopy. Thus, only women with both an HPV-positive result and cytological abnormalities are immediately referred for colposcopy. If the primary HPV test employs partial genotyping for HPV16 and HPV18, then direct referral colposcopy (without cytology) is possible \[[@B91-viruses-10-00729]\]. The same sample used for primary testing is recommended to be subsequently used for triage testing in order to reduce the risk of follow-up loss and maximize the efficiency of resources \[[@B47-viruses-10-00729],[@B55-viruses-10-00729],[@B91-viruses-10-00729],[@B99-viruses-10-00729]\]. Furthermore, primary HPV testing improves cytology screening by eliminating HPV-negative ASC-US cases, which constitute a considerable portion of borderline cytology and pose essentially no elevated risk for underlying CIN2/3 or cancer \[[@B77-viruses-10-00729],[@B83-viruses-10-00729],[@B91-viruses-10-00729]\]. Moreover, there is evidence that the predictive value of cytology readouts increases if the cytologist is aware of HPV status of the sample \[[@B88-viruses-10-00729]\].

To increase the specificity and improve the detection of precancerous lesions, other techniques, in addition to cytology, that could potentially be used for the triaging of women after a positive HPV primary test result are: partial HPV genotyping (HPV16/18 or extended), p16-Ki67 immunostaining, HPV E6/E7 mRNA detection, and cellular and viral methylation assays. However, at this time, there are insufficient data to favor such methods over cytology for triaging in Europe. The use of partial HPV genotyping triage is based on the fact that there is substantial variation in risk depending on HPV type, but it is still a matter of debate as to which HPV types other than HPV16 (HPV-18, HPV-31, HPV-33, HPV-45) it is worth implementing a routine risk-stratification algorithm \[[@B100-viruses-10-00729]\]. The p16/ki67 dual stain and HPV mRNA testing, have the potential to enable a more accurate distinction between transient HPV infections and those that will potentially progress to precancerous lesions/cancer. The p16/ki67 dual stain has been described as a credible tool that compares favorably to cytology, but both the p16/ki67 dual stain and HPV mRNA testing will need to become more cost-effective in order to compete with cytology. Methylation is in a similar predicament: it is still in the early stages but is displaying great potential as an accurate and promising molecular risk-stratification marker. The objectivity that this method offers, the consistency, and the high throughput potential will make methylation a strong candidate triaging method even if its performance is equivalent to that of cytology \[[@B55-viruses-10-00729],[@B101-viruses-10-00729],[@B102-viruses-10-00729]\].

### 4.3.2. Management of Women after a Positive HPV Primary Test Result and Negative Cytology Triage Results {#sec4dot3dot2-viruses-10-00729}

HPV-positive, cytology triage-negative women are recommended to undergo a different path than women with triage-positive cytology and/or borderline cytological results. Cytology triage-negative women who are infected by hrHPV, are still at risk for persistent infection and thus, require repeat testing at shorter intervals than HPV-negative women \[[@B83-viruses-10-00729]\]. The open issue is how to select the most appropriate follow-up test and intervals for repeat testing. The European Guidelines report that at present the evidence available is not sufficient to definitively recommend a single approach for all settings \[[@B55-viruses-10-00729]\] and as such provide three strategies for repeat testing ([Figure 1](#viruses-10-00729-f001){ref-type="fig"}). It is important to note that HPV retesting may be performed after at least 12 months, while cytology retesting can be performed after 6--12 months \[[@B99-viruses-10-00729],[@B103-viruses-10-00729],[@B104-viruses-10-00729]\]. As shown in [Figure 1](#viruses-10-00729-f001){ref-type="fig"}, the European Guidelines recommend that if HPV retesting is performed, a woman with a negative repeat HPV test is recommended to return to routine screening, while a woman with a positive result should be referred to colposcopy. If cytology retesting is performed, a woman with abnormal cytology should be referred for colposcopy, whereas a woman with negative cytology could return to routine screening. If HPV testing with cytology triage in repeat testing is performed it can be managed as follows: A woman with a negative HPV result can return to routine testing. However, a woman with a positive HPV result and abnormal cytology should be referred immediately for colposcopy. A woman with a positive HPV result and negative cytology can be referred to undergo repeat testing after 12 months, for colposcopy, or return to routine screening \[[@B99-viruses-10-00729],[@B105-viruses-10-00729],[@B106-viruses-10-00729]\]. A recent study, however, discourages the use of HPV repeat testing since women who test repeatedly HPV positive and cytology negative still have an increased risk for CIN2+ even after a repeat an HPV-negative test \[[@B88-viruses-10-00729],[@B107-viruses-10-00729]\]. This finding also indicates the lack of sufficient evidence regarding repeat testing, and thus, prior to the implementation of HPV based screening in repeat screening, the decision makers of each program have to consider the prevalence of HPV types in the target population as well as the quality of cytology in that region \[[@B55-viruses-10-00729]\].

### 4.3.3. Post-Treatment Follow-up {#sec4dot3dot3-viruses-10-00729}

Following the referral of a patient for colposcopy, the identification of high-grade cervical lesions may be diagnosed after biopsy (in approximately a quarter of referred women), followed by surgical treatment. Various treatments of high-grade cervical lesions are available, including cryotherapy, laser, loop electrosurgical excision procedure (LEEP) or large loop excision of the transformation zone (LLETZ) and cone biopsy, which are all characterized by an overall high success rate. However, treatment may fail with regard to residual or recurrent precancer, with 5--15% of treated women being diagnosed again with CIN2+ and therefore requiring additional therapy. Indeed, women once diagnosed with high-grade lesions are characterized by an increased lifetime risk of developing cervical cancer \[[@B47-viruses-10-00729],[@B108-viruses-10-00729]\]. Therefore, the increased risk of cancer highlights the importance of close post-treatment monitoring (follow-up testing) with the objective of early identification of residual/recurrent disease \[[@B108-viruses-10-00729],[@B109-viruses-10-00729],[@B110-viruses-10-00729]\]. For many years, the Pap test has been the most widely employed follow-up test, despite having relatively low sensitivity in this setting. Since 2008, the European Guidelines have recommended the performance of cytology 6, 12, and 24 months after CIN2+ treatment as main follow-up test \[[@B111-viruses-10-00729],[@B112-viruses-10-00729],[@B113-viruses-10-00729]\]. Nonetheless, there is growing evidence for the use of HPV testing in post-treatment monitoring, either alone or as cotesting. Importantly, cotesting achieves only marginally higher sensitivity than cytology or HPV testing alone, implying that HPV testing can be safely used without cytology \[[@B109-viruses-10-00729],[@B113-viruses-10-00729],[@B114-viruses-10-00729]\]. A study analyzing pooled data from 33 published studies argues in favor of follow-up hrHPV testing by noting that it had higher sensitivity for underlying CIN2+ and comparable sensitivity to that of cytology. In the same study it was also stated that women with positive surgical margins may benefit more from hrHPV testing due to very high PPV and NPV \[[@B109-viruses-10-00729]\]. Nevertheless, large-scale RCTs are required to establish the best follow-up algorithms after treatment of high-grade lesions \[[@B109-viruses-10-00729]\].

5. The Current Landscape of Cervical Cancer Screening in the E.U. and Some E.U.-Associated Countries {#sec5-viruses-10-00729}
====================================================================================================

5.1. The Implementation Status of Organized Population-Based Programs for Cervical Cancer Screening {#sec5dot1-viruses-10-00729}
---------------------------------------------------------------------------------------------------

Considering the pros and cons of all available cervical cancer screening tests, and despite the existence of evidence-based recommendations, it is clear that there is no "one size fits all" model for cervical cancer screening. There are various factors affecting the implementation of a screening program: the amount of healthcare funds available in each region/country, the preexisting medical and economic infrastructure, and the risk perception and tolerance of the society \[[@B87-viruses-10-00729]\]. [Table 1](#viruses-10-00729-t001){ref-type="table"}, which presents the data of each country regarding their cervical cancer screening programs, collected through meticulous bibliographical search, shows clearly that there is significant variation in the way members of the E.U., as well as some E.U. associated countries, address the matter of cervical cancer screening ([Table 1](#viruses-10-00729-t001){ref-type="table"}). Thus, the most recent official survey of implementation status of cervical cancer screening in the E.U. showed that although substantial improvement in screening implementation was documented in last decade and that a total of 22 member states were implementing, piloting, or planning the population-based cervical cancer screening program in 2016, the roll-out of the screening programs was completed in only nine out of 28 member states: Denmark, Estonia, Finland, Latvia, Poland, Slovenia, Sweden, The Netherlands, and The United Kingdom \[[@B115-viruses-10-00729]\], along with one E.U. associated country, Norway \[[@B116-viruses-10-00729]\]. There are countries among them that do not yet have organized population-based programs, namely, Austria, Bulgaria, Cyprus, Germany, Greece, Luxembourg, Spain, Israel, and Switzerland. However, even though these countries lack the abovementioned screening program, some of them have in place programs with certain elements of organized programs, mostly as a result of recommendations issued by the country's government and/or national gynecological/medical societies. In Austria, for example, a nationwide opportunistic program was created in 1970 to screen for cervical cancer. The program has remained opportunistic and is loosely structured by recommendations from Austrian medical societies, and the expenses are covered by health insurance \[[@B117-viruses-10-00729],[@B118-viruses-10-00729],[@B119-viruses-10-00729],[@B120-viruses-10-00729]\]. In Israel, screening is recommended and fully covered by the National Health Insurance Law, and furthermore, the Israeli Gynecological Society recommends the extension of screening ages from 35--54 to 25--65 \[[@B121-viruses-10-00729],[@B122-viruses-10-00729]\]. A similar situation is noted in Switzerland, where recommendations are offered by the Swiss Gynecological Society, and Pap testing is covered by health insurance \[[@B123-viruses-10-00729]\].

Some of these countries which are still lacking organized national screening programs have made attempts to implement national and/or regional screening programs ([Table 1](#viruses-10-00729-t001){ref-type="table"}). In 2009, Bulgaria initiated the "Stop and Get Checked" cancer screening program, which ended in 2014 with no scaling up \[[@B115-viruses-10-00729],[@B322-viruses-10-00729]\]. In Cyprus, the Ministry of Health, the Department of Medical and Public Health Services, assigned a temporary committee in 2008 with the intention of implementing a national screening program for cervical cancer in 2009 \[[@B118-viruses-10-00729]\]; however, the program was not realized, and screening is currently opportunistic. Nonetheless, a regional pilot screening program in Cyprus, organized by a private organization of women in cooperation with governmental health services as well as the support of the Ministry of Health, was initiated in 2012 and is still in effect \[[@B152-viruses-10-00729]\]. Similarly, in Greece, a number of regional cervical cancer screening programs have been reported, and there have also been efforts to establish a national organized population-based screening program for cervical cancer. These efforts have not been fruitful yet, reportedly due to the financial crisis \[[@B206-viruses-10-00729]\]. In Luxembourg, a national cervical cancer screening program was initiated in 1962, and it is currently opportunistic, run by a single national cytology laboratory \[[@B234-viruses-10-00729],[@B236-viruses-10-00729]\]. In Spain, screening at a national level is opportunistic, and there are variations in screening recommendations in different regions. In addition, some regions have their own population-based programs. Several scientific Spanish societies recommend the implementation of an organized screening program with HPV primary screening \[[@B92-viruses-10-00729],[@B269-viruses-10-00729],[@B278-viruses-10-00729]\]. Germany, however, with the passing of the Cancer Screening and Registration Law of 2013, has planned for an organized population-based cervical cancer screening program, which was reported to be scheduled for implementation by 2018 \[[@B197-viruses-10-00729]\]. In France, despite the existence of organized population-based programs, the country has been primarily characterized by opportunistic screening. National guidelines were published in 2010 for the initiation of a population-based cervical cancer screening program, and they are expected to be implemented nationwide in 2018 \[[@B185-viruses-10-00729]\]. In Lithuania, the program is organized but still has some opportunistic qualities, since the general practitioners (GPs) are the ones instructing patients to attend cervical cancer screening instead of the process being governed by an organized call-recall system and the invitations being sent out by mail \[[@B232-viruses-10-00729]\]. In Turkey, there are both organized and opportunistic programs, but the opportunistic approach is employed to a higher degree. An organized screening program implemented in 2004 was characterized by low coverage and redesigned in 2014 to include primary HPV testing, with the additional implementation of HPV vaccination being debated as well \[[@B312-viruses-10-00729],[@B315-viruses-10-00729],[@B316-viruses-10-00729],[@B317-viruses-10-00729],[@B318-viruses-10-00729]\]. Besides Turkey, other countries covered in this review that have yet to implement an HPV vaccination program are Bulgaria, Poland, Romania and Slovakia, indicating that HPV vaccination programs have been adopted by the majority of members of the E.U. and E.U. associated countries. As presented in [Table 1](#viruses-10-00729-t001){ref-type="table"} and depicted in [Figure 2](#viruses-10-00729-f002){ref-type="fig"}, out of the 32 countries covered in this review, only five countries do not have a national HPV vaccination program running \[[@B131-viruses-10-00729]\].

5.2. The Implementation Status of Primary HPV Testing {#sec5dot2-viruses-10-00729}
-----------------------------------------------------

As it can be observed from the data in [Table 1](#viruses-10-00729-t001){ref-type="table"}, which provides the implementation status of HPV primary testing in each country, there is a recent movement towards HPV-based primary screening, which has been embraced by some countries and is currently being strongly considered by others ([Figure 3](#viruses-10-00729-f003){ref-type="fig"}). Finland, Germany, Italy, The Netherlands, Sweden, The United Kingdom, Norway, and Turkey are all either in the process of implementing HPV primary screening on a regional or national level or have done so recently. Distinctions should be noted for Norway, where a regional pilot program for HPV primary testing is underway, and Finland, where HPV primary screening is implemented by some municipalities \[[@B175-viruses-10-00729],[@B184-viruses-10-00729]\]. In France, primary HPV testing has been studied in regional pilot programs \[[@B6-viruses-10-00729],[@B115-viruses-10-00729],[@B186-viruses-10-00729]\]. Romania is currently using cotesting in some regions and reportedly the strategy is to change to HPV primary screening during the 2017--2020 National Cancer Control Plan \[[@B115-viruses-10-00729],[@B257-viruses-10-00729]\]. Cotesting was also employed for a pilot study in two regions of Poland \[[@B248-viruses-10-00729]\] and for some regions in Portugal \[[@B251-viruses-10-00729]\]. Moreover, cotesting is also being performed in a pilot population-based program that is still ongoing in Malta \[[@B115-viruses-10-00729]\]. Other countries, such as Denmark, which performs HPV testing for women in the age range of 60--64 \[[@B169-viruses-10-00729],[@B170-viruses-10-00729]\] and Belgium \[[@B138-viruses-10-00729]\], are still evaluating HPV primary screening for implementation in their national programs.

5.3. The Importance of Coverage and Acceptance of Cervical Cancer Screening Programs {#sec5dot3-viruses-10-00729}
------------------------------------------------------------------------------------

Despite all the efforts to implement screening programs, their success depends primarily on sufficient population coverage. Unfortunately, many countries report suboptimal participation in screening programs \[[@B210-viruses-10-00729],[@B211-viruses-10-00729],[@B229-viruses-10-00729],[@B232-viruses-10-00729],[@B315-viruses-10-00729]\]. In an effort to increase coverage, in addition to educational campaigns and invitation reminders, many countries are also exploring or implementing self-sampling for nonparticipants \[[@B183-viruses-10-00729],[@B204-viruses-10-00729],[@B293-viruses-10-00729],[@B307-viruses-10-00729],[@B309-viruses-10-00729],[@B323-viruses-10-00729],[@B324-viruses-10-00729]\]. This testing strategy is also mentioned in the European Guidelines; however, they recommend that successful self-sampling pilot projects precede implementation. Furthermore, it is important to emphasize that self-sampling should be performed for HPV testing and not cytology \[[@B55-viruses-10-00729],[@B325-viruses-10-00729]\]. HPV self-sampling has been reported to have similar sensitivity and specificity as testing performed on samples taken by trained professionals. However, European Guidelines do not recommend self-sampling for all women, since, although they performed similarly, the results of self-collected samples are less accurate than those of samples collected by clinicians \[[@B55-viruses-10-00729]\]. The acceptability of self-sampling for HPV testing was shown in an RCT, where 99% of the samples returned were adequate for analysis, indicating that self-sampling can be a valid alternative for nonparticipants \[[@B326-viruses-10-00729]\].

Low coverage is directly affected by the targeted population, and accordingly, there have been numerous studies in various countries evaluating the awareness, perception, and knowledge of the population in regard to HPV, cervical cancer screening programs and vaccination programs \[[@B141-viruses-10-00729],[@B172-viruses-10-00729],[@B205-viruses-10-00729],[@B209-viruses-10-00729],[@B219-viruses-10-00729],[@B247-viruses-10-00729],[@B251-viruses-10-00729],[@B255-viruses-10-00729],[@B258-viruses-10-00729],[@B283-viruses-10-00729],[@B320-viruses-10-00729],[@B321-viruses-10-00729]\]. These studies also highlight the importance of health care providers, general practitioners and gynecologists, both in opportunistic screening and in organized programs \[[@B128-viruses-10-00729],[@B207-viruses-10-00729],[@B327-viruses-10-00729]\]. As indicated in [Table 1](#viruses-10-00729-t001){ref-type="table"} and illustrated in [Figure 4](#viruses-10-00729-f004){ref-type="fig"}, GPs and gynecologists tend to be the primary figures in opportunistic screening, performing the examinations and collecting the specimens, while in organized settings, the specimen can be can be collected by a variety of medically qualified individuals, such as nurses and midwives. These factors emphasize the importance of all affected parties in the movement towards organized population-based HPV primary screening. All parties must work together in order to achieve success, whether an already existing cytology-based organized program is upgraded to HPV-based program or a new organized program is implemented in a country previously performing opportunistic screening only.

6. Conclusions {#sec6-viruses-10-00729}
==============

Cervical cancer is an important health care problem in many parts of the world as well as in the E.U. It is a disease with a clearly defined natural history caused by essentially one etiological agent, and with long clinical latency. These characteristics of the disease enabled the development of acceptable and valid testing, such as the Pap test that was invented in the 1940s, to identify the precursor lesions, which can be treated in a safe, effective and acceptable way. This subsequently led to the establishment of routine cervical cancer screening in the 1960s. Primary prevention of cervical cancer was implemented more recently with the release of the first prophylactic HPV vaccine in 2006. Currently, the European Guidelines recommend organized population-based screening with primary HPV testing. However, this paradigm shift requires either the reformation of currently existing cytology-based organized programs or the implementation of new programs for countries still relying on opportunistic screening, which also mainly use cytology as a screening tool. The existing cytology-based screening programs are in many instances inefficient and costly because of the subjective nature of cytology, threatening to strain the public health budget of many countries, an effect that is expected to be exacerbated further as population HPV vaccination coverage increases \[[@B84-viruses-10-00729]\]. We are all fully aware that the implementation of functioning HPV-based organized cervical screening programs with accessible and effective treatment of precancerous lesions, coupled with universal gender-neutral HPV vaccination, is challenging for some of the E.U. member states, however, this is certainly the only way forward. When adequately combined, these two promising prevention options have the potential to dramatically reduce cervical cancer incidence and mortality.
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![Management algorithm in primary HPV screening. Abnormal cytology refers to a borderline or more severe cytological result. This algorithm was developed based on "The supplements of the second edition of the European Guidelines for Quality Assurance in Cervical Cancer Screening of 2015" \[[@B55-viruses-10-00729]\].](viruses-10-00729-g001){#viruses-10-00729-f001}

![The implementation status of HPV vaccination in E.U. member states and some E.U. associated countries as of 15 May 2018, based on the World Health Organization (WHO) "Vaccine in National Immunization Program Update". Source: <http://www.who.int/immunization/monitoring_surveillance/data/en/>; assessed for the last time on 16 July 2018 \[[@B131-viruses-10-00729]\]. The magnifying glass serves to enlarge the island of Malta.](viruses-10-00729-g002){#viruses-10-00729-f002}

![The implementation status of primary HPV testing in E.U. member states and some E.U. associated countries. The magnifying glass serves to enlarge the island of Malta. It is important to state that this is a rapidly changing field and that the status of implementation could not be confirmed for all countries from two independent sources.](viruses-10-00729-g003){#viruses-10-00729-f003}

![Health care providers that act as sample takers in cervical cancer screening programs in E.U. member states and some E.U. associated countries. The magnifying glass serves to enlarge the island of Malta. It is important to state that this is a rapidly changing field and that the status of implementation could not be confirmed from two independent sources and that this is a rapidly changing field. This figure was designed based on information available in [Table 1](#viruses-10-00729-t001){ref-type="table"} and Basu et al., 2017 \[[@B115-viruses-10-00729]\].](viruses-10-00729-g004){#viruses-10-00729-f004}

viruses-10-00729-t001_Table 1

###### 

Data regarding cervical cancer screening and human papillomavirus (HPV) vaccination programs of European Union (E.U.) members and some E.U. associated countries.

  Countries                       Presence and Type of Cervical Screening Program (Year of Initiation)   Screening Ages (Years)              Screening Interval (Years)                        Primary Screening Test Used                              Sample Taker                                                  Use of HPV Testing                                                                     HPV Vaccine in the National Immunization Program (Year of Initiation)   References
  ------------------------------- ---------------------------------------------------------------------- ----------------------------------- ------------------------------------------------- -------------------------------------------------------- ------------------------------------------------------------- -------------------------------------------------------------------------------------- ----------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **E.U. Member Countries**                                                                                                                                                                                                                                                                                                                                                                                                                                                          
  **Austria**                     Opportunistic                                                          18+ or 2 years after sexual onset   1                                                 CC                                                       GYN, GPs                                                      HPV testing funded in certain cases                                                    2014                                                                    \[[@B117-viruses-10-00729],[@B120-viruses-10-00729],[@B124-viruses-10-00729],[@B125-viruses-10-00729],[@B126-viruses-10-00729],[@B127-viruses-10-00729],[@B128-viruses-10-00729],[@B129-viruses-10-00729],[@B130-viruses-10-00729],[@B131-viruses-10-00729]\]
  **Belgium ^1^**                 Organized population-based, in some regions, roll-out ongoing, 2013    25--64                              3                                                 CC & LBC                                                 GYN, GPs                                                      HPV triage testing                                                                     2010: Flemish community, 2011: French community                         \[[@B131-viruses-10-00729],[@B132-viruses-10-00729],[@B133-viruses-10-00729],[@B134-viruses-10-00729],[@B135-viruses-10-00729],[@B136-viruses-10-00729],[@B137-viruses-10-00729],[@B138-viruses-10-00729],[@B139-viruses-10-00729],[@B140-viruses-10-00729],[@B141-viruses-10-00729],[@B142-viruses-10-00729],[@B143-viruses-10-00729]\]
  **Bulgaria**                    Opportunistic                                                          N/A                                 N/A                                               N/A                                                      GPs                                                           N/A                                                                                    \-                                                                      \[[@B115-viruses-10-00729],[@B131-viruses-10-00729],[@B144-viruses-10-00729],[@B145-viruses-10-00729],[@B146-viruses-10-00729],[@B147-viruses-10-00729],[@B148-viruses-10-00729]\]
  **Croatia**                     Organized population-based, roll-out ongoing, 2012                     25--64                              3                                                 CC                                                       GYN                                                           HPV triage testing, test for cure                                                      2016                                                                    \[[@B115-viruses-10-00729],[@B131-viruses-10-00729],[@B149-viruses-10-00729],[@B150-viruses-10-00729]\]
  **Cyprus ^2^**                  Opportunistic                                                          N/A                                 N/A                                               N/A                                                      GYN                                                           N/A                                                                                    2016                                                                    \[[@B131-viruses-10-00729],[@B151-viruses-10-00729],[@B152-viruses-10-00729],[@B153-viruses-10-00729],[@B154-viruses-10-00729]\]
  **Czech Republic**              Organized population-based, roll-out ongoing, 2008                     15+                                 1                                                 CC                                                       GYN                                                           HPV triage testing                                                                     2012                                                                    \[[@B115-viruses-10-00729],[@B131-viruses-10-00729],[@B155-viruses-10-00729],[@B156-viruses-10-00729],[@B157-viruses-10-00729],[@B158-viruses-10-00729],[@B159-viruses-10-00729],[@B160-viruses-10-00729]\]
  **Denmark**                     Organized population-based, 2006                                       23--64                              3 (ages: 23--59); 5 (ages: 60--64)                LBC (ages: 23--59); HPV test (ages: 60--64)              GYN, GPs                                                      HPV primary testing performed for the ages 60--64, HPV triage testing, test for cure   2009                                                                    \[[@B6-viruses-10-00729],[@B131-viruses-10-00729],[@B161-viruses-10-00729],[@B162-viruses-10-00729],[@B163-viruses-10-00729],[@B164-viruses-10-00729],[@B165-viruses-10-00729],[@B166-viruses-10-00729],[@B167-viruses-10-00729],[@B168-viruses-10-00729],[@B169-viruses-10-00729],[@B170-viruses-10-00729],[@B171-viruses-10-00729]\]
  **Estonia**                     Organized population-based, 2006                                       30--59                              5                                                 CC                                                       GYN, Midwives                                                 Not in use                                                                             2018                                                                    \[[@B6-viruses-10-00729],[@B131-viruses-10-00729],[@B172-viruses-10-00729],[@B173-viruses-10-00729],[@B174-viruses-10-00729]\]
  **Finland ^3^**                 Organized population-based, 1963                                       25/30--60/65                        5                                                 CC, HPV test                                             Midwives, Nurses                                              HPV primary testing in some regions, HPV triage testing                                2013                                                                    \[[@B131-viruses-10-00729],[@B175-viruses-10-00729],[@B176-viruses-10-00729],[@B177-viruses-10-00729],[@B178-viruses-10-00729],[@B179-viruses-10-00729],[@B180-viruses-10-00729],[@B181-viruses-10-00729],[@B182-viruses-10-00729],[@B183-viruses-10-00729],[@B184-viruses-10-00729]\]
  **France**                      Transitioning to organized population-based planned for 2018, 1991     25--64                              3 (CC), 5 (HPV test)                              CC & LBC (ages: 25--64); HPV test (ages: 30--64)         GYN, GPs, Midwives                                            HPV primary testing in regional pilot projects, HPV triage testing                     2007                                                                    \[[@B6-viruses-10-00729],[@B115-viruses-10-00729],[@B131-viruses-10-00729],[@B142-viruses-10-00729],[@B160-viruses-10-00729],[@B185-viruses-10-00729],[@B186-viruses-10-00729],[@B187-viruses-10-00729],[@B188-viruses-10-00729],[@B189-viruses-10-00729],[@B190-viruses-10-00729],[@B191-viruses-10-00729],[@B192-viruses-10-00729]\]
  **Germany**                     Transitioning to organized population-based planned for 2018, 1971     20+                                 1                                                 CC                                                       GYN                                                           HPV primary testing in implementation, HPV triage testing                              2007                                                                    \[[@B64-viruses-10-00729],[@B115-viruses-10-00729],[@B131-viruses-10-00729],[@B160-viruses-10-00729],[@B193-viruses-10-00729],[@B194-viruses-10-00729],[@B195-viruses-10-00729],[@B196-viruses-10-00729],[@B197-viruses-10-00729],[@B198-viruses-10-00729],[@B199-viruses-10-00729],[@B200-viruses-10-00729],[@B201-viruses-10-00729]\]
  **Greece ^4^**                  Opportunistic                                                          Sexual onset                        1                                                 CC                                                       GYN, GPs                                                      Not in use                                                                             2008                                                                    \[[@B128-viruses-10-00729],[@B131-viruses-10-00729],[@B202-viruses-10-00729],[@B203-viruses-10-00729],[@B204-viruses-10-00729],[@B205-viruses-10-00729],[@B206-viruses-10-00729],[@B207-viruses-10-00729]\]
  **Hungary**                     Organized population-based, roll-out ongoing, 2003                     25--65                              3                                                 CC                                                       GYN, Primary care personnel                                   Not in use                                                                             2014                                                                    \[[@B6-viruses-10-00729],[@B115-viruses-10-00729],[@B131-viruses-10-00729],[@B208-viruses-10-00729],[@B209-viruses-10-00729],[@B210-viruses-10-00729],[@B211-viruses-10-00729],[@B212-viruses-10-00729],[@B213-viruses-10-00729],[@B214-viruses-10-00729]\]
  **Ireland**                     Organized population-based, roll-out ongoing, 2008                     25--60                              3 (ages: 25--44); 5 (ages: 45--60)                LBC                                                      Various healthcare providers termed registered smear-takers   HPV triage testing, test for cure                                                      2010                                                                    \[[@B6-viruses-10-00729],[@B115-viruses-10-00729],[@B131-viruses-10-00729],[@B215-viruses-10-00729],[@B216-viruses-10-00729],[@B217-viruses-10-00729],[@B218-viruses-10-00729],[@B219-viruses-10-00729]\]
  **Italy ^3^**                   Organized population-based, roll-out ongoing, 1989                     25--64                              3 (ages: 25--30/35); 5 (ages: 30/35--64)          CC & LBC (ages: 25--30/35); HPV test (ages: 30/34--64)   Midwives, Nurses                                              HPV primary testing in some regions, HPV triage testing, test for cure                 2008                                                                    \[[@B6-viruses-10-00729],[@B115-viruses-10-00729],[@B118-viruses-10-00729],[@B131-viruses-10-00729],[@B220-viruses-10-00729],[@B221-viruses-10-00729],[@B222-viruses-10-00729],[@B223-viruses-10-00729],[@B224-viruses-10-00729],[@B225-viruses-10-00729],[@B226-viruses-10-00729],[@B227-viruses-10-00729]\]
  **Latvia**                      Organized population-based, 2009                                       25--69                              3                                                 CC                                                       GYN, GPs                                                      Not in use                                                                             2010                                                                    \[[@B6-viruses-10-00729],[@B131-viruses-10-00729],[@B228-viruses-10-00729],[@B229-viruses-10-00729],[@B230-viruses-10-00729],[@B231-viruses-10-00729]\]
  **Lithuania**                   Organized population-based, roll-out ongoing, 2004                     25--59                              3                                                 CC                                                       GYN, GPs                                                      Not in use                                                                             2016                                                                    \[[@B6-viruses-10-00729],[@B67-viruses-10-00729],[@B115-viruses-10-00729],[@B131-viruses-10-00729],[@B232-viruses-10-00729],[@B233-viruses-10-00729]\]
  **Luxembourg**                  Opportunistic                                                          15+                                 1                                                 LBC                                                      GYN, GPs                                                      HPV triage testing                                                                     2008                                                                    \[[@B131-viruses-10-00729],[@B234-viruses-10-00729],[@B235-viruses-10-00729],[@B236-viruses-10-00729],[@B237-viruses-10-00729],[@B238-viruses-10-00729],[@B239-viruses-10-00729]\]
  **Malta**                       Organized population-based, (Piloting), 2015                           25--35                              3                                                 CC & HPV test                                            Doctors, Nurses                                               Cotesting                                                                              2012                                                                    \[[@B67-viruses-10-00729],[@B115-viruses-10-00729],[@B131-viruses-10-00729],[@B159-viruses-10-00729],[@B160-viruses-10-00729],[@B240-viruses-10-00729]\]
  **Netherlands**                 Organized population-based, 1970                                       30--64                              5                                                 HPV test                                                 GPs, Physicians, Clinicians, Midwives                         HPV primary testing, HPV triage testing                                                2010                                                                    \[[@B87-viruses-10-00729],[@B115-viruses-10-00729],[@B131-viruses-10-00729],[@B241-viruses-10-00729],[@B242-viruses-10-00729],[@B243-viruses-10-00729],[@B244-viruses-10-00729],[@B245-viruses-10-00729],[@B246-viruses-10-00729]\]
  **Poland**                      Organized population-based, 2006                                       25--59                              3                                                 CC (ages: 25--59); CC & HPV test (ages: 30--59)          GYN, Midwives                                                 Regional pilot for Cotesting, HPV triage testing                                       \-                                                                      \[[@B6-viruses-10-00729],[@B115-viruses-10-00729],[@B131-viruses-10-00729],[@B160-viruses-10-00729],[@B247-viruses-10-00729],[@B248-viruses-10-00729],[@B249-viruses-10-00729],[@B250-viruses-10-00729]\]
  **Portugal ^3^**                Organized population-based, in some regions, roll-out ongoing, 1990    25--59                              3                                                 CC & LBC                                                 GPs                                                           Cotesting in some regions                                                              2008                                                                    \[[@B115-viruses-10-00729],[@B131-viruses-10-00729],[@B251-viruses-10-00729],[@B252-viruses-10-00729],[@B253-viruses-10-00729],[@B254-viruses-10-00729]\]
  **Romania ^5^**                 Organized population-based, in some regions, roll-out ongoing, 2012    25--64                              5                                                 CC & HPV test                                            GYN, GPs                                                      Cotesting in some regions                                                              \-                                                                      \[[@B115-viruses-10-00729],[@B131-viruses-10-00729],[@B255-viruses-10-00729],[@B256-viruses-10-00729],[@B257-viruses-10-00729],[@B258-viruses-10-00729],[@B259-viruses-10-00729],[@B260-viruses-10-00729]\]
  **Slovakia**                    Transitioning to organized population-based, 2008                      23--64                              Yearly x 2; then 3 yearly                         CC                                                       GYN                                                           HPV triage testing                                                                     \-                                                                      \[[@B75-viruses-10-00729],[@B115-viruses-10-00729],[@B131-viruses-10-00729],[@B147-viruses-10-00729],[@B159-viruses-10-00729],[@B261-viruses-10-00729],[@B262-viruses-10-00729],[@B263-viruses-10-00729],[@B264-viruses-10-00729]\]
  **Slovenia**                    Organized population-based, 2003                                       20--64                              Yearly x 2; then 3 yearly                         CC                                                       GYN                                                           HPV triage testing, test of cure                                                       2009                                                                    \[[@B6-viruses-10-00729],[@B115-viruses-10-00729],[@B131-viruses-10-00729],[@B147-viruses-10-00729],[@B160-viruses-10-00729],[@B265-viruses-10-00729],[@B266-viruses-10-00729],[@B267-viruses-10-00729],[@B268-viruses-10-00729]\]
  **Spain ^3^**                   Opportunistic                                                          25--65                              3                                                 CC                                                       GYN, Nurses, Midwives                                         HPV triage testing in some regions                                                     2007                                                                    \[[@B92-viruses-10-00729],[@B115-viruses-10-00729],[@B118-viruses-10-00729],[@B131-viruses-10-00729],[@B160-viruses-10-00729],[@B269-viruses-10-00729],[@B270-viruses-10-00729],[@B271-viruses-10-00729],[@B272-viruses-10-00729],[@B273-viruses-10-00729],[@B274-viruses-10-00729],[@B275-viruses-10-00729],[@B276-viruses-10-00729],[@B277-viruses-10-00729],[@B278-viruses-10-00729]\]
  **Sweden**                      Organized population-based, 1967                                       23--60                              3 (ages: 23--50); 5 (ages: 51--60)                HPV test replacing CC & LBC                              Midwives                                                      HPV primary testing in some regions HPV triage testing, test for cure                  2012                                                                    \[[@B114-viruses-10-00729],[@B115-viruses-10-00729],[@B131-viruses-10-00729],[@B142-viruses-10-00729],[@B279-viruses-10-00729],[@B280-viruses-10-00729],[@B281-viruses-10-00729],[@B282-viruses-10-00729],[@B283-viruses-10-00729],[@B284-viruses-10-00729],[@B285-viruses-10-00729],[@B286-viruses-10-00729]\]
  **United Kingdom**              Organized population-based, 1988                                       25--64                              3 (ages: 25--49); 5 (ages: 50--64)                HPV test replacing LBC                                   GYN, GPs, Nurses, Midwives                                    HPV primary testing in implementation, HPV triage testing, test for cure               2008                                                                    \[[@B115-viruses-10-00729],[@B128-viruses-10-00729],[@B131-viruses-10-00729],[@B287-viruses-10-00729],[@B288-viruses-10-00729],[@B289-viruses-10-00729],[@B290-viruses-10-00729],[@B291-viruses-10-00729],[@B292-viruses-10-00729],[@B293-viruses-10-00729]\]
  **E.U. Associated Countries**                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  **Norway**                      Organized population-based, 1995                                       25--69                              3                                                 CC & LBC, HPV test                                       GYN, GPs                                                      Regional pilot for HPV primary testing, HPV triage testing                             2009                                                                    \[[@B131-viruses-10-00729],[@B294-viruses-10-00729],[@B295-viruses-10-00729],[@B296-viruses-10-00729],[@B297-viruses-10-00729],[@B298-viruses-10-00729],[@B299-viruses-10-00729]\]
  **Israel**                      Opportunistic                                                          35--54                              3                                                 LBC                                                      GYN, Obstetricians                                            Not in use                                                                             2013                                                                    \[[@B121-viruses-10-00729],[@B122-viruses-10-00729],[@B131-viruses-10-00729],[@B300-viruses-10-00729],[@B301-viruses-10-00729],[@B302-viruses-10-00729],[@B303-viruses-10-00729],[@B304-viruses-10-00729]\]
  **Switzerland**                 Opportunistic                                                          Sexual onset/21--70                 2 (ages: Sexual onset/21--29); 3 (ages: 30--70)   CC & LBC                                                 GYN, GPs                                                      HPV triage testing                                                                     2008                                                                    \[[@B69-viruses-10-00729],[@B123-viruses-10-00729],[@B131-viruses-10-00729],[@B305-viruses-10-00729],[@B306-viruses-10-00729],[@B307-viruses-10-00729],[@B308-viruses-10-00729],[@B309-viruses-10-00729],[@B310-viruses-10-00729],[@B311-viruses-10-00729]\]
  **Turkey**                      Organized population-based, roll-out ongoing, 2004                     30--65                              5                                                 HPV test, CC & LBC,                                      GYN, Doctors, Nurses                                          HPV primary testing                                                                    \-                                                                      \[[@B131-viruses-10-00729],[@B312-viruses-10-00729],[@B313-viruses-10-00729],[@B314-viruses-10-00729],[@B315-viruses-10-00729],[@B316-viruses-10-00729],[@B317-viruses-10-00729],[@B318-viruses-10-00729],[@B319-viruses-10-00729],[@B320-viruses-10-00729],[@B321-viruses-10-00729]\]

Conventional cytology; LBC = liquid-based cytology; GP = general practitioner; N/A = not available, GYN = gynecologists; "-" = HPV vaccine not in the national immunization program. ^1^ In Belgium an organized population-based program is in place only in the Flemish region \[[@B138-viruses-10-00729]\]. ^2^ In Cyprus a regional pilot screening program was initiated in 2012, which is still in effect \[[@B152-viruses-10-00729]\]. ^3^ In Finland, Italy, Portugal and Spain there is variation depending on the region. There are some regions in Spain that have population-based programs \[[@B92-viruses-10-00729],[@B175-viruses-10-00729],[@B184-viruses-10-00729],[@B220-viruses-10-00729],[@B251-viruses-10-00729],[@B269-viruses-10-00729],[@B278-viruses-10-00729],[@B312-viruses-10-00729]\]. ^4^ In Greece, there are some regional cervical cancer screening programs that have been reported \[[@B206-viruses-10-00729]\]. ^5^ In Romania an HPV vaccination program had started in 2008 but it was discontinued due to low uptake \[[@B256-viruses-10-00729],[@B257-viruses-10-00729],[@B259-viruses-10-00729]\].
